The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease

E-ISSN： 1875-533x|21|27|3188-3210

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.27, 2014-09, pp. : 3188-3210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A2A Receptor Ligands: Past, Present and Future Trends

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 9, 2010-06 ,pp. : 902-922

Bentham Science Publishers

Access to resources Recommend Favorite

Dopamine Agonists in the Treatment of Parkinsons Disease-Past, Present and Future

Current Pharmaceutical Design, Vol. 6, Iss. 12, 2000-08 ,pp. : 1211-1248

Bentham Science Publishers

Access to resources Recommend Favorite

Dopamine D Receptors: Relevance for the Drug Treatment of Parkinson's Disease

By Levant B.

CNS Drugs, Vol. 12, Iss. 5, 1999-11 ,pp. : 391-402

Adis International

Access to resources Recommend Favorite

Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists

By Kadieva M. Oganesyan É. Mutsueva S.

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 10, 2005-10 ,pp. : 520-532

Springer Publishing Company

Access to resources Recommend Favorite

An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 6, 2011-09 ,pp. : 659-669

Bentham Science Publishers

Access to resources Recommend Favorite